Ingenol Mebutate 500 µg on the Cheekbones with Concomitant Conjunctivitis.

Détails

ID Serval
serval:BIB_63077C215DAF
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Etude de cas (case report): rapporte une observation et la commente brièvement.
Collection
Publications
Institution
Titre
Ingenol Mebutate 500 µg on the Cheekbones with Concomitant Conjunctivitis.
Périodique
Dermatology (Basel, Switzerland)
Auteur⸱e⸱s
Gaide O., Cattin V.
ISSN
1421-9832 (Electronic)
ISSN-L
1018-8665
Statut éditorial
Publié
Date de publication
2016
Peer-reviewed
Oui
Volume
232 Suppl 1
Pages
4-6
Langue
anglais
Notes
Publication types: Case Reports ; Journal Article
Publication Status: ppublish
Résumé
Ingenol mebutate induces strong inflammation after a single application already. This must be taken into account when prescribing the drug, as mistakes in the application may results in severe side effects. Here, we report the case of a 72-year-old woman who applied ingenol mebutate on the cheekbones and developed a pronounced conjunctivitis, needing topical corticosteroids. The treatment was intended for the actinic keratosis she had on the chest, and the regimen of 2 consecutive once daily applications of ingenol mebutate at 500 µg/g had been prescribed as registered. The inadvertent application on the thin skin of the cheekbones led to a pronounced inflammation. With topical steroids followed by fusidic acid, both conjunctivitis and skin inflammation resolved within a few days. The skin showed erythema for a few weeks, but after 3 months, the patient presented a perfectly smooth skin and was very happy with the cosmetic outcome. This suggests that the cheekbones are a sensitive site for ingenol mebutate, but that intense inflammation should not scare physician or patient, as clinical remission with excellent healing can still be expected.

Mots-clé
Administration, Topical, Aged, Anti-Bacterial Agents/administration & dosage, Antineoplastic Agents/administration & dosage, Antineoplastic Agents/adverse effects, Cheek, Conjunctivitis/chemically induced, Conjunctivitis/drug therapy, Dermatologic Agents/administration & dosage, Dermatologic Agents/adverse effects, Diterpenes/administration & dosage, Diterpenes/adverse effects, Female, Glucocorticoids/administration & dosage, Humans, Keratosis, Actinic/drug therapy
Pubmed
Open Access
Oui
Création de la notice
15/09/2016 21:34
Dernière modification de la notice
20/08/2019 15:19
Données d'usage